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FLUORESCENT DIAGNOSIS AND PHOTODYNAMIC THERAPY FOR 
C6 GLIOMA IN COMBINATION WITH ANTIANGIOGENIC THERAPY 
IN SUBCUTANEOUS AND INTRACRANIAL TUMOR MODELS
D.A. Tzerkovsky*, V.V. Osharin, Y.P. Istomin, E.N. Alexandrova, M.A. Vozmitel
N.N. Alexandrov National Cancer Center of Belarus, 223040 Minsk, Belarus
Objective: Investigating the distinctions pharmacokinetics of chlorin e6 conjugated with polyvinyl pyrrolidone photosensitizer (Ce6CPPPS)
in healthy and tumor tissues of rat brain and evaluating the antitumor efficacy of combination treatment for C6 rat glioma including 
photodynamic (PDT) and antiangiogenic therapy (AAT). Materials and Methods: The study was performed on 50 white random-bred 
rats in subcutaneous and intracranial models of C6 glioma. Photosensitizer (PS) Ce6CPPPS single injection at a dose of 2.5 mg/kg was 
made into the animal’s caudal vein. The PS accumulation level in brain tissues and C6 rat glioma was measured with spectral fluorescence 
technique using LESA-01-Biospek spectrum analyser (Russian Federation, Moscow; λ = 632.8 nm). Photoirradiation of intracranial 
and subcutaneous C6 glioma was carried out with a light exposure dose of 50 J/cm2 (IMAF-Axicon, Republic of Belarus; λ = 661 nm). 
AAT drug bevacizumab, single injection was made intravenously at a dose of 10 mg/kg 24 h after tumor photoirradiation. The criteria for 
efficacy evaluation were mean survival time (MST) and median survival of the animals in the study group vs the control and the  percentage 
of tumor necrosis areas induced by the above-mentioned treatment. Results: The optimal time for photoirradiation of intracranial 
C6 glioma is 0.5 h after Ce6CPPPS injection. The combination therapy group demonstrated a statistically significant MST increase 
(38.4 ± 4.39 days) compared with the PDT group (29.2 ± 3.5 days) (p = 0.02) and the AAT group (27.1 ± 2.74 days) (p = 0.02). Necro-
sis areas in tumor tissue were as follows: the intact control — 10.0 ± 2.55%, PDT — 54.87 ± 6.95% (p = 0.003), AAT — 57.83 ± 6.53% 
(p = 0.003) and combination therapy — 89.43 ± 5.57% (p = 0.001). Conclusions: This paper is the first report about feasibility of efficient 
use of PDT with a PS of chlorin series and AAT with bevacizumab for the treatment of brain tumors in experimental models.
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Malignant brain tumors have acquired social sig-
nificance, being in many respects an unsettled issue. 
Over the past decade, the mean malignant brain tumors 
incidence rate of 550 new patients a year was registered 
in Belarus [1]. The malignant brain tumors treatment in-
cludes combination modalities: surgical ablation of the tu-
mor, radio- and chemotherapy. The major limitation for 
surgical intervention is insufficient visu alization of tumor 
margins and its location in functionally important brain 
areas. In most of cases radical tumor resection is impos-
sible as the excision of healthy brain tissue with tumor cells 
infiltrating it may cause severe neurological morbidity. Ra-
dio- and chemotherapy are employed mainly in the post-
operative period to affect the area of subclinical tumor 
spread. The median survival after radiotherapy does not 
exceed 10–12 months, after stereotaxic radiotherapy — 
5–14 months, with surgery or radiosurgery in combination 
with radiotherapy — 12–16 months [2–4]. Local (intersti-
tional) hyperthermia, laser therapy, exposure of focused 
ultrasound have certain potentials for malignant brain 
tumors. However, the aforesaid treatment modalities have 
limited indications for their use. They are mostly utilized 
in the cases of conventional treatment modalities failing 
to produce the expected curative effect [5, 6].
At present, the current malignant brain tumors 
treatment modalities have reached their limits. 
A painstaking search is being made for novel alterna-
tive treatment modes for this disease. One of them 
is photodynamic therapy (PDT). The PDT technique 
is based on the use of the effect of selective laser pho-
todestruction of tumor tissue sensitized beforehand. 
The efficacy of photodynamic damage of the sensi-
tized cell is determined by intracellular concentration 
and location of the sensitizer, its photochemical activity 
and the light dose of laser irradiation [7, 8].
A number of experiments in vitro [9–11] and 
in vivo [12, 13], as well as clinical studies [14, 15] 
confirmed PDT efficacy for brain tumors, using he-
matoporphyrins, aminolevulinic acid derivatives and 
chlorins as photosensitizers (PS).
In the recent years, several scientific studies dealt 
with investigation of neoangiogenesis in brain tumors 
and sought new ways to disrupt its links. One of such 
avenues is antiangiogenic therapy (AAT). Since glial 
tumors are among the most vascularized ones, they 
are an excellent target to be hit by AAT. The inhibition 
of vascular endothelial growth factor (VEGF) expression 
resulted in considerably reduced growth of glial cells. 
Moreover, AAT administration facilitated restoration 
of normal blood flow, decreased hypoxia and increased 
of tumor cell sensitivity to radio- and chemotherapy [16].
The most known and advantageous drug in VEGF 
blocker series is bevacizumab which is a humanized 
monoclonal antibody. The first findings on possible ef-
ficiency of bevacizumab in combination with irinotecan 
in high-grade glioma management were published 
by V. Stark-Vance in 2005. The objective response rate 
in his study was 43% [17–19].
The results of the research demonstrated a signifi-
cant rise of survival rates, improvement or stabilization 
of the neurocognitive function and also a decrease 
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in steroid doses in malignant brain tumors treatment 
using AAT [20, 21]. However, the interest in AAT em-
ployment has been recently declining due to the ab-
sence of the expected improvement of long-term 
outcomes and high cost of the targeted drugs [22, 23].
Thus the issue of the search for new approach-
es to the management of malignant glial tumors 
of the brain is left open. A very promising approach 
is the combination of two and more treatments modali-
ties for this disease. There are a few reports  supporting 
the feasibility of efficient and safe use of PDT with 
porphyrin PS and AAT with monoclonal antibodies [24]. 
These studies are purely experimental ones needing 
further investigation and development.
The objective of this study is to investigate chlorin 
e6 conjugated with polyvinyl pyrrolidone photosensitizer 
(Ce6CPPPS) pharmacokinetics in healthy and tumor tis-
sues of rat brain and to evaluate the antitumor efficacy 
of the treatment modality including PDT with Ce6CPPPS 
and AAT with bevacizumab in an in vivo experimental 
model.
MATERIALS AND METHODS
The study was conducted on 50 white rats (160 ± 20 g) 
bred in the vivarium of N.N. Alexandrov National Cancer 
Center of Belarus. Animal experiments were performed 
according to the Rules of Ethic Committee.
The experimental research on Ce6CPPPS phar-
macokinetics in healthy and tumor tissues of rat brain 
was carried out on 10 laboratory animals.
The experimental research in vivo on the antitumor 
efficacy of the proposed treatment modality was done 
on 40 laboratory animals distributed to 4 groups, 10 rats 
in each: group 1 — intact control, group 2 — PDT, 
group 3 — AAT and group 4 — combination therapy.
The tumor strain. The research was done on the ex-
perimental tumor strain of C6 glioma. The tumor cell 
culture was obtained from the National Center of Epide-
miology and Microbiology (Minsk, Republic of Belarus).
Subcutaneous experimental tumor model. 
To evaluate tumor sensitivity to the above-mentioned 
modalities, subcutaneous tumor implantation was made 
into the left inguinal region by injection 0.5 ml of 20% 
tumor suspension in 0.6% Hanks’ solution. The treat-
ments were administered 11–13 days after C6 glioma 
implantation, with tumor diameter reaching 1.5–2.0 сm.
The orthotopic model of experimental tumor. 
To create the orthotopic model of experimental tu-
mor, intracranial implantation of C6 glioma was made. 
A trephine opening was drilled with a bur 1.5 mm in dia-
meter in the rats skull, 3.0 mm off the sagittal suture 
in the in the left parietal region, after the animal having 
been introduced into the state of neuroleptanalgesia 
(0.1% phentanyl + 0.025% droperidol). Tumor cells 
in 25 μl of DMEM medium, 500•106 cells in number, were 
implanted in the projection of the left lateral ventricle with 
a syringe having a restrictor at the end of the needle [25].
PS. A single injection of the PS Photolon (RUE 
“Belmedpreparaty”, Minsk, Republic of Belarus) was 
made at a dose of 2.5 mg/kg into the animal’s caudal vein.
Fluorescent diagnostics. The PS accumula-
tion level was measured with spectral fluorescence 
technique using LESA-01-Biospek spectrum analyser 
(Russian Federation, Moscow; λ = 632.8 nm).
AAT. A single intravenous injection of Avastin® 
(bevacizumab, F. Hoffmann-La Roche Ltd.) for AAT was 
made at a dose of 10 mg/kg.
PDT. The PDT treatment was carried out 0.5 h after 
Ce6CPPPS administration. Photoirradiation of intracra-
nial C6 glioma with a light exposure dose of 50 J/cm2 was 
performed through the trephine opening on day 17 af-
ter tumor cell inoculation, with clinical sings of tumor 
growth being apparent. The semiconductor laser unit 
“IMAF-Axicon” (Minsk, Republic of Belarus; λ = 661 nm) 
was used as a radiation source.
The same light energy exposure dose was used for 
subcutaneously implanted tumors. The PDT treatment 
was conducted 2.5 h after Ce6CPPPS injection [26].
Criteria for antitumor efficacy evaluation. The effi-
cacy of the therapy was evaluated by C6 glioma pathomor-
phism, by the data on mean survival time (MST), median 
survival and by induced necrosis areas in the tumor, using 
the technique of intravital staining of the bloodstream 
channel with 0.6% Evans blue solution.
Statistical processing of the results. Statistical 
processing of survival outcomes was done with the Ka-
plan — Meier method using log-rank test (statistical 
software package Statistica 8.0). To evaluate necrosis 
areas in tumor tissue, a special ImageJ program (NIH, 
Bethesda, USA) was applied. Statistical significance 
of differences was relevant at p < 0.05.
RESULTS AND DISCUSSION
At the first stage of the research, to evaluate 
the time of PDT administration after PS injection, 
the dynamics of its accumulation was investigated 
in healthy and tumor tissues of the brain on days 
15–19 after tumor cell implantation. The Ce6CPPPS 
accumulation level was measured 0, 1, 3, 6 and 24 h af-
ter PS injection. The results are presented in Fig. 1.
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Fig. 1. The dynamics of Ce6CPPPS fluorescence intensity 
in healthy brain tissue and in C6 glioma after its 2.5 mg/kg injection
Our experimental findings pertaining to Ce6CPPPS 
PS accumulation in healthy brain tissues and C6 glioma 
obtained using the technique of laser-induced flu ore-
scence spectroscopy in vivo, validate high tropism 
of this agent to C6 glioma tissues in laboratory animals.
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Fig. 2. C6 glioma. The state after AAT (a, c), combination 
therapy (b) and PDT (d) 
Based on the data on Ce6CPPPS accumulation 
dynamics, C6 glioma photoirradiation was performed 
with the maximal value of PS fluorescence signal 
in tumor tissue. Ce6CPPPS and bevacizumab were 
injected in groups 2 and 3, in the combination therapy 
group bevasizumab was administrated 24 h after PDT, 
laser photoirradiation of the tumor being carried out 
at a light exposure dose of 50 J/cm2 0.5 h after PS in-
jection (group 4). Tumor pathomorphism was evalu-
ated 72 h after PDT (group 2) and AAT (group 3), and 
48 h after bevacizumab administration in combination 
therapy group (group 4).
A PDT treatment resulted in local necrotic changes 
in the exposure area without thermodestruction 
of tumor and brain tissue. In addition to consider-
able necrosis areas, hemorrhage foci were noted, 
mainly in the central parts of the lesion. Hemorrhages 
and insignificant edema in the tissue surrounding 
the tumor growth region were observed in the normal 
parenchyma encircling the tumor. The combination 
therapy produced a synergetic effect manifested 
in a proportional extension of necrosis areas in tumor 
tissue. The results obtained are presented in Fig. 2.
Our study investigated sensitivity of C6 glioma sub-
cutaneously implanted into the rat’s right inguinal area. 
According to our findings, all the animals subjected 
to combination therapy presented with necrotic chang-
es of maximal size 72 h after the treatment. In the control 
group, this index showing the emergence of sponta-
neous central necrosis was insignificant. The results 
obtained are presented in Fig. 2–4 and the Table.
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Fig. 3. Histotopographic sections of C6 glioma in the control 
group (a), after AAT (10 mg/kg bevacizumab) (b), after PDT 
with Ce6CPPPS (2.5 mg/kg, 50 J/cm2) (c) and after combina-
tion therapy (PDT with Ce6CPPPS (2.5 mg/kg, 50 J/cm2) + AAT 
(10 mg/kg bevacizumab) (d)
In conclusion, the study of distinctions of Ce-
6CPPPS pharmacokinetics in healthy and tumor tis-
sues of rat brain validated the fact of high tropism 
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of this PS to C6 rat glioma. The spectral fluorescent 
diagnostic technique determined the optimal time 
of PDT treatments for intracranial tumor. PS concen-
tration was demonstrated to reach its maximal value 
0.5 h after Ce6CPPPS injection into tumor tissues.
Table. MST and median survival rates and tumor tissue necrosis indices 
in the control and study groups
Group MST, days Median, days p
Necrosis 
area, % p
Intact control 15.4 ± 1.95 16 – 10 ± 2.55 –
AAT* 27.1 ± 2.74 27 0.02 57.83 ± 6.53 0.003
PDT* 29.2 ± 3.5 29 0.02 54.87 ± 6.95 0.003
Combination therapy 38.4 ± 4.39 40 0.01 89.43 ± 5.57 0.001
Note: *p = 0.31 (AAT vs PDT)
Cumulative Proportion Surviving (Kaplan — Meier)
Complete  Censored
 Control  PDT
 AAT  Combination therapy
5 10 15 20 25 30 35 40 45 50
Time
-0,1
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
Cu
m
ul
at
ive
 P
ro
po
rti
on
 S
ur
viv
in
g
Fig. 4. Survival curves of animals with C6 glioma regarding 
treatment modality
Antitumor efficacy of malignant brain tumors 
treatment modalities was evaluated in an experi-
ment on ani mals. The Table presents necrosis areas 
on histotopographic sections of subcutaneously trans-
planted glioma C6 after AAT 10 mg/kg bevacizumab), 
PDT with Ce6CPPPS at the light dose 50 J/cm2 and 
combination therapy (PDT with Ce6CPPPS at the light 
dose 50  J/ cm2) + AAT (10 mg/kg bevacizumab) being 
performed 2.5 h after PS administration at a dose 
of 2.5 mg/kg. The percentage of tumor necrosis areas 
was 57.83 ± 6.53%, 54.87 ± 6.95% and 89.43 ± 5.57%, 
respectively (p = 0.001). Also showed a significant in-
crease in MST and median survival rates of laboratory 
animals with intracranial С6 glioma in the combination 
therapy group compared with each of its components 
individually (38.4 ± 4.39; 40 days vs 27.1 ± 2.74; 
27 days and 29.2 ± 3.5; 29 days; p = 0.01). Our data 
on MST, median survival of the animals and patho-
mophological changes in tumor tissue demonstrated 
that PDT with Ce6CPPPS and AAT with bevacizumab 
improved treatment outcomes in animals with experi-
mental brain tumors.
The studies in this field are at the stage of ex-
perimental substantiation. This paper is the first re-
port about feasibility of efficient use of PDT with 
a PS of chlorine series and AAT with bevacizumab 
for the treatment of brain tumors in experimental 
models. Our findings demonstrate that the tumor 
strain, implanted either subcutaneously or intracrani-
ally, is sensible to the proposed treatment regimen. 
However, E. Lindsay et al. reported that intracranial 
rat gliomas are less sensible to PDT with m-THPP 
(porphyrin derivate) than subcutaneously implanted 
ones. The authors attiribute this fact to hematoence-
phalic barrier impeding the penetration of sufficient 
PS amount to the tumor tissue, needed to achieve 
the curative effect, and also to the peculiarities of tu-
mor blood supply [27].
The findings of our experimental study cor-
roborate high tropism of Ce6CPPPS to C6 rat glioma 
which is associated with the possibility of  penetrating 
through hematoencephalic barrier, and sizable in-
crease in antitumor efficacy of PDT in its combination 
with AAT.
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